Want to see FATE full AI Analyst Report?
Top Page
Fate Therapeutics
(NASDAQ:FATE)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.50
▼(-2.72% Downside)
Action:Reiterated
Date:09/29/26
The score is weighed down primarily by weak financial performance—unstable revenue, large ongoing losses, and persistent cash burn alongside a shrinking equity cushion. Technicals are mixed with soft near-term momentum, while valuation lacks support due to a negative P/E and no dividend. Offsetting these risks, the $15M CIRM grant is a meaningful positive catalyst that improves near-term funding and validates the FT819 program.
Positive Factors
Non-dilutive clinical funding
The $15M CIRM grant provides non-dilutive funding for FT819’s lupus nephritis development, extending resources without an immediate equity raise. It also represents external validation of the program and supports continued advancement toward a potentially registrational trial.
Negative Factors
No recurring commercial product revenue
Without approved products generating recurring sales, Fate remains dependent on collaboration-related payments and future milestones rather than an established commercial revenue base. That makes revenue visibility less durable and leaves financial progress closely tied to development and partnering outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive clinical funding
The $15M CIRM grant provides non-dilutive funding for FT819’s lupus nephritis development, extending resources without an immediate equity raise. It also represents external validation of the program and supports continued advancement toward a potentially registrational trial.
Read all positive factors
Fate Therapeutics (FATE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$277.98M
Dividend YieldN/A
Average Volume (3M)1.36M
Price to Earnings (P/E)―
Beta (1Y)2.76
Revenue Growth-23.36%
EPS Growth27.52%
CountryUS
Employees161
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.05
Shares Outstanding119,820,510
10 Day Avg. Volume1,355,427
30 Day Avg. Volume1,360,254
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue38.05
Enterprise Value/Gross Profit-11.09
Enterprise Value/Ebitda-2.11
Forecast
1Y Price Target
$6.70Price Target Upside160.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$5.65M
Fate Therapeutics Business Overview & Revenue Model
Company Description
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A sign...
How the Company Makes Money
Fate Therapeutics does not have publicly established, recurring product sales from approved therapies; as a clinical-stage company, its revenue has primarily been generated from collaboration and licensing arrangements rather than commercial produ...
Fate Therapeutics Earnings Call Summary
Earnings Call Date:May 09, 2024
(Q1-2024)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in clinical trials, particularly with FT819 and FT522, alongside a strong financial position. However, revenue growth remains limited and operating expenses are high, suggesting a balanced outlook with promising clinical achievements countered by financial challenges.Positive Updates
FT819 and FT522 Data Presentation
Presented promising data from FT819 and FT522 programs at the ASGCT Annual Meeting, showing potential disease-modifying effects and immune reset in B-cell-mediated autoimmune diseases.
Negative Updates
Limited Revenue Growth
Reported revenue of $1.9 million, consistent with prior quarters, reflecting limited growth.
Read all updates
Q1-2024 Updates
Positive
Negative
FT819 and FT522 Data Presentation
Presented promising data from FT819 and FT522 programs at the ASGCT Annual Meeting, showing potential disease-modifying effects and immune reset in B-cell-mediated autoimmune diseases.
Read all positive updates
Company Guidance
During the Fate Therapeutics Q1 2024 earnings call, the company provided guidance on its clinical and financial outlook. Key program initiatives were discussed, including the FT819 CAR T-cell and FT522 CAR NK cell programs, with notable translational data presented at the American Society of Gene and Cell Therapy Annual Meeting. The company highlighted its plans to achieve several clinical milestones across its iPSC product pipeline, targeting both cancer and autoimmune diseases. Financially, Fate Therapeutics raised $100 million through an underwritten offering and private placement, ending the first quarter with approximately $391 million in cash. Operating expenses for the full year are projected between $215 million and $230 million, with a year-end cash balance exceeding $270 million. The company's strategic focus is on demonstrating the disease-modifying potential of its therapies while maintaining a strong financial position to support ongoing and future clinical development.Fate Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.49M | 6.65M | 13.63M | 63.53M | 96.30M | 55.85M |
| Gross Profit | -22.27M | -6.25M | -104.90M | -93.65M | 82.54M | 50.00M |
| EBITDA | -117.18M | -127.02M | -176.58M | -142.65M | -267.96M | -206.30M |
| Net Income | -126.00M | -136.31M | -186.26M | -160.93M | -281.72M | -212.15M |
Balance Sheet | ||||||
| Total Assets | 260.10M | 318.94M | 440.69M | 506.22M | 705.56M | 921.46M |
| Cash, Cash Equivalents and Short-Term Investments | 153.77M | 203.66M | 279.07M | 315.18M | 436.23M | 615.91M |
| Total Debt | 75.67M | 77.85M | 85.27M | 103.54M | 109.34M | 114.82M |
| Total Liabilities | 106.67M | 111.75M | 121.97M | 137.80M | 221.62M | 242.62M |
| Stockholders Equity | 153.44M | 207.18M | 318.73M | 368.42M | 483.94M | 678.84M |
Cash Flow | ||||||
| Free Cash Flow | -105.66M | -112.04M | -123.60M | -138.42M | -283.77M | -213.57M |
| Operating Cash Flow | -101.94M | -106.08M | -122.87M | -132.26M | -248.21M | -162.87M |
| Investing Cash Flow | 87.05M | 111.17M | 12.22M | 112.67M | 166.75M | -324.02M |
| Financing Cash Flow | 5.90M | 5.49M | 99.89M | 85.00K | 9.21M | 453.13M |
Fate Therapeutics Technical Analysis
Negative
2.57
Price Trends
2.48
Negative
2.43
Negative
1.85
Positive
Market Momentum
-0.04
Positive
42.22
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FATE, the sentiment is Negative. The current price of 2.57 is above the 20-day moving average (MA) of 2.41, above the 50-day MA of 2.48, and above the 200-day MA of 1.85, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 42.22 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FATE.
Fate Therapeutics Risk Analysis
Fate Therapeutics disclosed 90 risk factors in its most recent earnings report. Fate Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Fate Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $218.82M | 6.15 | 42.57% | ― | 234.18% | ― | |
56 Neutral | $675.44M | -13.20 | -43.57% | ― | -66.63% | 57.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $87.13M | -1.87 | -103.08% | ― | -6.96% | 32.77% | |
49 Neutral | $277.98M | -2.21 | -65.08% | ― | -23.36% | 27.52% | |
46 Neutral | $184.43M | -1.64 | -39.64% | ― | ― | -6.70% | |
45 Neutral | $80.46M | -2.61 | 1020.21% | ― | ― | 2.05% |
* Healthcare Sector Average
FATE
Fate Therapeutics
2.32
0.91
64.54%
CGEN
Compugen
2.31
0.52
29.05%
ONCY
Oncolytics Biotech
0.63
-0.73
-53.60%
CRDF
Cardiff Oncology
1.12
-1.08
-49.09%
NKTX
Nkarta
2.58
0.43
19.77%
STTK
Shattuck Labs
6.73
4.14
159.85%
Fate Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Fate Therapeutics Secures CIRM Grant for FT819 Lupus Trial
Positive
Sep 28, 2026
On September 25, 2026, Fate Therapeutics announced that the California Institute for Regenerative Medicine awarded the company a $15 million CLIN2 grant to support RECLAIM-LN, its Phase 2 potentially registrational trial of FT819 in patients with ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.